Medicare evaluating coverage for $56,000 Alzheimer's drug

FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. Congressional investigators have asked the maker of an Alzheimer’s drug to turn over information about how the company developed and priced the medication. The letter Monday, July 12, 2021 to Biogen is the opening salvo in a previously announced investigation into Aduhelm, an expensive and unproven therapy that has sparked scrutiny since winning U.S. approval last month. (Biogen via AP, File)

Medicare's announcement came on the same day that Democratic leaders of two House committees asked drugmaker Biogen to turn over reams of documents on how it developed and priced the drug, and on its dealings with government officials at the Food and Drug Administration. Although pricey drugs are now fairly commonplace, the recent approval of Aduhelm prompted an unusually intense backlash. The FDA went against the recommendation of its outside advisers in granting the approval, and the beleaguered agency has since curtailed the recommended use of the drug and requested an investigation by an independent watchdog into its dealings with Biogen.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting